国际站：Tocilizumab

CAS：375823-41-9

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Tocilizumab (Anti-Human IL6R, Humanized Antibody) 是一种抗人白细胞介素 6 受体 (IL-6R) 中和抗体，可阻止 IL-6 与 IL-6R 结合，从而抑制两种经典的和转信令。 Tocilizumab (Anti-Human IL6R, Humanized Antibody) 可用于治疗类风湿性关节炎^[1]。 Tocilizumab 对于严重 COVID-19（冠状病毒病）的研究非常有效^[4]。 IC50 和目标：IC50：IL-6R^[1]

体外：Tocilizumab（抗人 IL6R，人源化抗体）（1-100 ng/mL；24 小时、48 小时）以剂量依赖性方式抑制细胞增殖（生长速率），HACM 的生长速率几乎完全降低 100 ng /mL tocilizumab^[2].Tocilizumab（抗人 IL6R，人源化抗体）（0.001-10,000 μg/ml；2 天）抑制 Ba/F3-gp130-IL-6R 细胞用 hIL-6 刺激增殖，IC₅₀ 为 13.5 ng/ml^[1]。Tocilizumab（抗人 IL6R，人源化抗体）（1 μM ; 6 小时）在体外降低 STAT3 的磷酸化，与体内 SAS 细胞一致^[3]。Tocilizumab（抗人 IL6R，人源化抗体）（1-5 μM；24 小时)用无血清培养基显着降低SAS细胞中VEGF mRNA的表达^[3]。

体内：Tocilizumab（抗人 IL6R，人源化抗体）（静脉注射；1.0 mg/100 μL；每周两次，三周）减少注射了 tocilizumab 的小鼠大脑中每个转移灶的体积^[2] .Tocilizumab（抗人 IL6R，人源化抗体）（腹膜内注射；100 μg/mL，每 48 小时一次；20 天）抑制 OSCC 进展并抑制肿瘤血管生成^[3]。

参考文献：[1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.[2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.[3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.[4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.